SynthesisTranslational psychiatry2022
Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis.
Synthesis in Translational psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Guideline
- Comorbid health outcomes in patients with schizophrenia: an umbrella review of systematic reviews and meta-analyses.Molecular psychiatry · 2025Pooled it
- Evidence-Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders.Current psychiatry reports · 2023Pooled it
- Effectiveness and safety of aripiprazole oral solution in the acute treatment of schizophrenia in Chinese patients.BMC psychiatry · 2024Trial
- Gender differences in cognitive function in antipsychotic-treated chronic schizophrenia patients with hyperprolactinemia: a large-scale cross-sectional study.European archives of psychiatry and clinical neuroscience · 2026Article
- Efficacy and Safety of Risperidone Microspheres for Injection (II) in Patients With Schizophrenia Spectrum Disorders: A Prospective, Single-Arm, Multicenter Real-World Study.Alpha psychiatry · 2026Article
- Sexual Function and Depressive Symptoms in Metformin-Treated Women with Drug-Induced Hyperprolactinemia and Different Vitamin D Status: A Pilot Study.Pharmaceutics · 2026Article
- The prevalence of antipsychotic polypharmacy and its associations with violent behaviors among forensic psychiatry patients.BMC psychiatry · 2026Article
- Risk of hyperprolactinemia and extrapyramidal symptoms in antipsychotic-treated schizophrenia: a retrospective single-center real-world study.Frontiers in pharmacology · 2026Article
- Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect.Therapeutic advances in psychopharmacology · 2026Article
- Sexual dysfunction associated with antidepressants and antipsychotics: a structured narrative review of mechanisms, assessment, and personalized management.Frontiers in psychiatry · 2026Review
- Elevated prolactin and association with treatment resistance indicators in first-hospitalized schizophrenia spectrum disorders: a real-world cohort study.BMC psychiatry · 2025Article
- Reproductive and Fertility Care of Women with Schizophrenia: A Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- Aripiprazole alleviates the high prolactin levels induced by amisulpride via distinct molecular mechanisms: a network pharmacology and molecular docking study.BMC psychiatry · 2025Article
- Brexpiprazole in the Management of Schizophrenia: A Consensus Report of Best Practices From Acute to Maintenance Treatment.Neuropsychiatric disease and treatment · 2025Article
- Combinatorial classification model for predicting antipsychotic-induced hyperprolactinemia risk.American journal of translational research · 2025Article
- Real-world pharmacovigilance of risperidone: Analysis based on FAERS reports from physicians and pharmacists.PloS one · 2025Article
- Efficacy and Safety of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction in Schizophrenia: A Systematic Review and Meta-Analysis.Neuropsychiatric disease and treatment · 2025Review
- Severity and influencing factors of hyperprolactinemia in hospitalized schizophrenia patients: a cross-sectional study.Frontiers in psychiatry · 2025Article
- A giant fecaloma causing stercoral colitis secondary to aripiprazole and benztropine: A case report.Qatar medical journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antipsychotic-induced hyperprolactinemia (AP-induced HPRL) occurs overall in up to 70% of patients with schizophrenia, which is associated with hypogonadism and sexual dysfunction. We summarized the latest evidence for the benefits of prolactin-lowering drugs. We performed network meta-analyses to summarize the evidence and applied Grading of Recommendations Assessment, Development, and Evaluation frameworks (GRADE) to rate the certainty of evidence, categorize interventions, and present the findings. The search identified 3,022 citations, 31 studies of which with 1999 participants were included in network meta-analysis. All options were not significantly better than placebo among patients with prolactin (PRL) less than 50 ng/ml. However, adjunctive aripiprazole (ARI) (5 mg: MD = -64.26, 95% CI = -87.00 to -41.37; 10 mg: MD = -59.81, 95% CI = -90.10 to -29.76; more than 10 mg: MD = -68.01, 95% CI = -97.12 to -39.72), switching to ARI in titration (MD = -74.80, 95% CI = -134.22 to -15.99) and adjunctive vitamin B6 (MD = -91.84, 95% CI = -165.31 to -17.74) were associated with significant decrease in AP-induced PRL among patients with PRL more than 50 ng/ml with moderated (adjunctive vitamin B6) to high (adjunctive ARI) certainty of evidence. Pharmacological treatment strategies for AP-induced HPRL depends on initial PRL level. No effective strategy was found for patients with AP-induced HPRL less than 50 ng/ml, while adjunctive ARI, switching to ARI in titration and adjunctive high-dose vitamin B6 showed better PRL decrease effect on AP-induced HPRL more than 50 ng/ml.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.